"Final data from phase 2a study underscores potential for fostrox + Lenvima to become first approved option in second-line liver cancer" Financial summary for the quarterNet turnover amounted ...

Isolere Bio by Donaldson, an innovative bioprocessing technology provider, proudly announces the availability of its ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

It’s no secret that drug development is a huge ... have the economic luxury of decades-long development cycles, indication expansion can provide new treatment avenues for patients with few ...

Though not a new methodology ... data collection solutions like chart review studies that aid in development of tailored patient-level repositories of data are likely to become more common.

Tempus AI, Inc. TEM is scheduled to report first-quarter fiscal 2025 results on May 6. In the last reported quarter, the company’s adjusted loss of 18 cents was wider than the Zacks Consensus Estimate ...

Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can ...

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation in advanced solid tumors ...

Researchers from the University of Adelaide have developed a new technology for drug and functional genomics screenings, ...